Format

Send to

Choose Destination
Ann Oncol. 2016 Nov;27(11):2134-2136. Epub 2016 Aug 8.

Utilisation of the ESMO-MCBS in practice of HTA.

Author information

1
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria claudia.wild@hta.lbg.ac.at.
2
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
3
Independent Pharmaceutical Consultant, Mellieha, Malta.
4
Department of Finance, University of Vienna, Austria.
5
Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia.
6
Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania.
7
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
8
Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
9
Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University and State Medicines Control Agency, Vilnius, Lithuania.
10
Healthcare Improvement Scotland, Scottish Medicine Consortium, Glasgow, UK.
11
Agency for Health Technology Assessment and Tariff System, Warsaw, Poland.
PMID:
27502718
DOI:
10.1093/annonc/mdw297
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for Strathprints - the University of Strathclyde
Loading ...
Support Center